Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Real-world Adherence, Persistence, Switching, and Reinitiation in Patients Prescribed AJOVY in US Physician Practices
Headache
Headache Posters (7:00 AM-5:00 PM)
119

AJOVY (fremanezumab), a fully-humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), has been approved for preventive treatment of migraine in adults.

To assess real-world adherence, persistence, switching, and reinitiation among US patients prescribed AJOVY.

Data were obtained from the Veradigm Health Insights Electronic Health Records (EHR) Database. The study period was from January 1, 2014 to June 30, 2019. Patients aged ≥18 years were included if they had ≥1 migraine diagnosis during the study period and a medication record for AJOVY on or after the initial diagnosis date during the identification period (September 1, 2018 to December 31, 2018). Adherence, persistence, switching, and reinitiation were evaluated for patients who had dosing data. A gap of >45 days in the EHR was used to identify switching or reinitiation.

Overall, 987 patients prescribed AJOVY were included; 594 (60.2%) had episodic migraine and 393 (39.8%) had chronic migraine. Most patients were female (842 [85.3%]) and 41-64 years of age (595 [60.3%]). Anxiety (152 [15.4%]) and depression (143 [14.5%]) were the most common comorbidities during the baseline period. Based on proportion of days covered of ≥80% and medication possession ratio of ≥80%, 738 (74.8%) and 780 (79.0%) patients, respectively, were adherent. 746 (75.6%) patients were persistent for ≥6 months. Of 216 (21.9%) patients who discontinued AJOVY, 7 (3.2%) switched to other CGRP pathway-targeted treatments (Emgality or Aimovig), 89 (41.2%) switched to a different acute or non-specific preventive treatment class, 21 (9.7%) reinitiated AJOVY treatment, and 103 (47.7%) permanently discontinued any acute or preventive migraine therapy.

Real-world treatment adherence and persistence were high with AJOVY; the majority of patients who discontinued AJOVY treatment discontinued any treatment or switched to a different preventive treatment class, and several patients restarted AJOVY.

Authors/Disclosures
Krishna Tangirala (Teva ;Pharmaceuticals)
PRESENTER
Krishna Tangirala has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Joshua *use 125685 Cohen (Teva Pharmaceuticals Industries) Joshua Cohen has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Shivani Pandya (StatInMed) Shivani Pandya has received personal compensation for serving as an employee of StatInMed.
Lynda Krasenbaum Lynda Krasenbaum has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Chien-Cheng Chen Chien-Cheng Chen has received personal compensation for serving as an employee of StatInMed.
Stephen F. Thompson Stephen Thompson has received personal compensation for serving as an employee of Teva Pharmaceuticals.